MGAT2 and obesity disorder: To investigate the antidiabetic and anti‐obesity effects of pharmacological MGAT2 inhibition, CpdB (30 mg·kg−1) was administered orally once daily for 36 days in HFD‐ob/ob mice, which is a model of severe obesity and type 2 diabetes.